Skip to content

A Photodynamic Therapy for Treatment of Actinic Keratoses

A Photodynamic Therapy for Treatment of Actinic Keratoses

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00558688
Enrollment
20
Registered
2007-11-15
Start date
2007-08-31
Completion date
2009-08-31
Last updated
2021-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Actinic Keratoses

Brief summary

The purpose of this study is to compare the efficacy of photodynamic therapy with 5-aminolevulinic acid and intense pulsed light vs absence of treatment for actinic keratoses.

Detailed description

This study seeks to evaluate the efficacy of photodynamic therapy with 5-aminolevulinic acid and intense pulsed light vs. absence of treatment for actinic keratoses

Interventions

PROCEDUREPhotodynamic therapy

Photodynamic therapy applied to actinic keratoses

Sponsors

Northwestern University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

Age greater than or equal to 18 years * Have a t least 4 nonhypertrophic AK lesions on the body * The subjects are in good health * The subject has the willingness and the ability to understand and provide informed consent for the use of their tissue and communicate to the investigator

Exclusion criteria

* Subjects who are pregnant or lactating * Subjects with a history of cutaneous photosensitivity or porphyria, hypersensitivity to porphyrins, or photodermatosis * Subjects with use of photosensitizing drugs within 1 week of study start * Subjects with use of topical medications such as corticosteroids, alpha-hydroxyacids or retinoids 2 weeks before study entry * Subjects with systemic steroid therapy within 4 weeks before study entry * Subjects who received previous treatment of target AKs * Subjects with systemic treatment with chemotherapeutic agents, masoprocol (Actinex), immunotherapy, or retinoids within 2 months of study entry * Subjects with prior history of hypersensitivity reactions to lidocaine * Subjects who are unable to understand the protocol or to give informed consent

Design outcomes

Primary

MeasureTime frame
Visual assessment of lesions4 weeks

Secondary

MeasureTime frame
Patient subjective assessment and Safety4 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026